世界の神経変性疾患治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Neurodegenerative Diseases Drug Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z4088
• 出版社/出版日：QYResearch / 2021年4月
※2025年版があります。お問い合わせください。
• レポート形態：英文、PDF、92ページ
• 納品方法：Eメール（納期：3日）
• 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

レポート概要

QYResearch社発行の本調査資料では、神経変性疾患治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（免疫調節剤、インターフェロン、デカルボキシラーゼ阻害剤、ドーパミン作動薬、その他）、用途別市場規模（多発性硬化症、パーキンソン病、アルツハイマー病、脊髄性筋萎縮症（SMA）、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。
・市場概要
・神経変性疾患治療薬の市場動向
・企業の競争状況、市場シェア
・神経変性疾患治療薬の種類別市場規模（免疫調節剤、インターフェロン、デカルボキシラーゼ阻害剤、ドーパミン作動薬、その他）
・神経変性疾患治療薬の用途別市場規模（多発性硬化症、パーキンソン病、アルツハイマー病、脊髄性筋萎縮症（SMA）、その他）
・神経変性疾患治療薬の北米市場規模2016-2027（アメリカ、カナダ）
・神経変性疾患治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等）
・神経変性疾患治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等）
・神経変性疾患治療薬の中南米市場規模2016-2027（メキシコ、ブラジル）
・神経変性疾患治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等）
・主要企業情報（Biogen、Pfizer、Roche、Novartis、Sanofi、Teva Pharmaceuticals、Orion Pharma Ltd、UCB S.A、ACADIA Pharmaceuticals Inc.、Lundbeck Pharmaceuticals Italy S.p.A.、Mitsubishi Tanabe Pharma America）
・結論

Neurodegenerative disease is caused by the loss of neurons and/or their myelin sheath, which worsens over time and becomes dysfunctional.

Market Analysis and Insights: Global Neurodegenerative Diseases Drug Market
The global Neurodegenerative Diseases Drug market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neurodegenerative Diseases Drug market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neurodegenerative Diseases Drug market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neurodegenerative Diseases Drug market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neurodegenerative Diseases Drug market.

Global Neurodegenerative Diseases Drug Scope and Market Size
Neurodegenerative Diseases Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neurodegenerative Diseases Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
By Drug Class
Immunomodulator
Interferons
Decarboxylase Inhibitors
Dopamine Agonists
Others
By Route of Administration
Oral
Injection
Transdermal

Segment by Application
Multiple Sclerosis
Parkinson’s Disease
Alzheimer’s Disease
Spinal Muscular Atrophy (SMA)
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Biogen
Pfizer
Roche
Novartis
Sanofi
Teva Pharmaceuticals
Orion Pharma Ltd
UCB S.A
ACADIA Pharmaceuticals Inc.

レポート目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Diseases Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Immunomodulator
1.2.3 Interferons
1.2.4 Decarboxylase Inhibitors
1.2.5 Dopamine Agonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Diseases Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Multiple Sclerosis
1.3.3 Parkinson’s Disease
1.3.4 Alzheimer’s Disease
1.3.5 Spinal Muscular Atrophy (SMA)
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Neurodegenerative Diseases Drug Market Perspective (2016-2027)
2.2 Neurodegenerative Diseases Drug Growth Trends by Regions
2.2.1 Neurodegenerative Diseases Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neurodegenerative Diseases Drug Historic Market Share by Regions (2016-2021)
2.2.3 Neurodegenerative Diseases Drug Forecasted Market Size by Regions (2022-2027)
2.3 Neurodegenerative Diseases Drug Industry Dynamic
2.3.1 Neurodegenerative Diseases Drug Market Trends
2.3.2 Neurodegenerative Diseases Drug Market Drivers
2.3.3 Neurodegenerative Diseases Drug Market Challenges
2.3.4 Neurodegenerative Diseases Drug Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Diseases Drug Players by Revenue
3.1.1 Global Top Neurodegenerative Diseases Drug Players by Revenue (2016-2021)
3.1.2 Global Neurodegenerative Diseases Drug Revenue Market Share by Players (2016-2021)
3.2 Global Neurodegenerative Diseases Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Diseases Drug Revenue
3.4 Global Neurodegenerative Diseases Drug Market Concentration Ratio
3.4.1 Global Neurodegenerative Diseases Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Drug Revenue in 2020
3.5 Neurodegenerative Diseases Drug Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Diseases Drug Product Solution and Service
3.7 Date of Enter into Neurodegenerative Diseases Drug Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Neurodegenerative Diseases Drug Breakdown Data by Type
4.1 Global Neurodegenerative Diseases Drug Historic Market Size by Type (2016-2021)
4.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2022-2027)

5 Neurodegenerative Diseases Drug Breakdown Data by Application
5.1 Global Neurodegenerative Diseases Drug Historic Market Size by Application (2016-2021)
5.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Neurodegenerative Diseases Drug Market Size (2016-2027)
6.2 North America Neurodegenerative Diseases Drug Market Size by Type
6.2.1 North America Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
6.2.2 North America Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
6.2.3 North America Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
6.3 North America Neurodegenerative Diseases Drug Market Size by Application
6.3.1 North America Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
6.3.2 North America Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
6.3.3 North America Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
6.4 North America Neurodegenerative Diseases Drug Market Size by Country
6.4.1 North America Neurodegenerative Diseases Drug Market Size by Country (2016-2021)
6.4.2 North America Neurodegenerative Diseases Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Neurodegenerative Diseases Drug Market Size (2016-2027)
7.2 Europe Neurodegenerative Diseases Drug Market Size by Type
7.2.1 Europe Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
7.2.2 Europe Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
7.2.3 Europe Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
7.3 Europe Neurodegenerative Diseases Drug Market Size by Application
7.3.1 Europe Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
7.3.2 Europe Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
7.3.3 Europe Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
7.4 Europe Neurodegenerative Diseases Drug Market Size by Country
7.4.1 Europe Neurodegenerative Diseases Drug Market Size by Country (2016-2021)
7.4.2 Europe Neurodegenerative Diseases Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size (2016-2027)
8.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type
8.2.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application
8.3.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region
8.4.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Neurodegenerative Diseases Drug Market Size (2016-2027)
9.2 Latin America Neurodegenerative Diseases Drug Market Size by Type
9.2.1 Latin America Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
9.2.2 Latin America Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
9.2.3 Latin America Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
9.3 Latin America Neurodegenerative Diseases Drug Market Size by Application
9.3.1 Latin America Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
9.3.2 Latin America Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
9.3.3 Latin America Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
9.4 Latin America Neurodegenerative Diseases Drug Market Size by Country
9.4.1 Latin America Neurodegenerative Diseases Drug Market Size by Country (2016-2021)
9.4.2 Latin America Neurodegenerative Diseases Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size (2016-2027)
10.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type
10.2.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application
10.3.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country
10.4.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Neurodegenerative Diseases Drug Introduction
11.1.4 Biogen Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.1.5 Biogen Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neurodegenerative Diseases Drug Introduction
11.2.4 Pfizer Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Neurodegenerative Diseases Drug Introduction
11.3.4 Roche Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.3.5 Roche Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Neurodegenerative Diseases Drug Introduction
11.4.4 Novartis Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.4.5 Novartis Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Neurodegenerative Diseases Drug Introduction
11.5.4 Sanofi Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.5.5 Sanofi Recent Development
11.6 Teva Pharmaceuticals
11.6.1 Teva Pharmaceuticals Company Details
11.6.2 Teva Pharmaceuticals Business Overview
11.6.3 Teva Pharmaceuticals Neurodegenerative Diseases Drug Introduction
11.6.4 Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.6.5 Teva Pharmaceuticals Recent Development
11.7 Orion Pharma Ltd
11.7.1 Orion Pharma Ltd Company Details
11.7.2 Orion Pharma Ltd Business Overview
11.7.3 Orion Pharma Ltd Neurodegenerative Diseases Drug Introduction
11.7.4 Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.7.5 Orion Pharma Ltd Recent Development
11.8 UCB S.A
11.8.1 UCB S.A Company Details
11.8.2 UCB S.A Business Overview
11.8.3 UCB S.A Neurodegenerative Diseases Drug Introduction
11.8.4 UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.8.5 UCB S.A Recent Development
11.9 ACADIA Pharmaceuticals Inc.
11.9.1 ACADIA Pharmaceuticals Inc. Company Details
11.9.2 ACADIA Pharmaceuticals Inc. Business Overview
11.9.3 ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Introduction
11.9.4 ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.9.5 ACADIA Pharmaceuticals Inc. Recent Development
11.10 Lundbeck Pharmaceuticals Italy S.p.A.
11.10.1 Lundbeck Pharmaceuticals Italy S.p.A. Company Details
11.10.2 Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
11.10.3 Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Introduction
11.10.4 Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.10.5 Lundbeck Pharmaceuticals Italy S.p.A. Recent Development
11.11 Mitsubishi Tanabe Pharma America
11.11.1 Mitsubishi Tanabe Pharma America Company Details
11.11.2 Mitsubishi Tanabe Pharma America Business Overview
11.11.3 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Introduction
11.11.4 Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.11.5 Mitsubishi Tanabe Pharma America Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Neurodegenerative Diseases Drug Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Immunomodulator
Table 3. Key Players of Interferons
Table 4. Key Players of Decarboxylase Inhibitors
Table 5. Key Players of Dopamine Agonists
Table 6. Key Players of Others
Table 7. Global Neurodegenerative Diseases Drug Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Neurodegenerative Diseases Drug Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Neurodegenerative Diseases Drug Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Neurodegenerative Diseases Drug Market Share by Regions (2016-2021)
Table 11. Global Neurodegenerative Diseases Drug Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Neurodegenerative Diseases Drug Market Share by Regions (2022-2027)
Table 13. Neurodegenerative Diseases Drug Market Trends
Table 14. Neurodegenerative Diseases Drug Market Drivers
Table 15. Neurodegenerative Diseases Drug Market Challenges
Table 16. Neurodegenerative Diseases Drug Market Restraints
Table 17. Global Neurodegenerative Diseases Drug Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Neurodegenerative Diseases Drug Market Share by Players (2016-2021)
Table 19. Global Top Neurodegenerative Diseases Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Diseases Drug as of 2020)
Table 20. Ranking of Global Top Neurodegenerative Diseases Drug Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Neurodegenerative Diseases Drug Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neurodegenerative Diseases Drug Product Solution and Service
Table 24. Date of Enter into Neurodegenerative Diseases Drug Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neurodegenerative Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2016-2021)
Table 28. Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Neurodegenerative Diseases Drug Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Neurodegenerative Diseases Drug Revenue Market Share by Application (2016-2021)
Table 32. Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Neurodegenerative Diseases Drug Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Neurodegenerative Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Neurodegenerative Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Neurodegenerative Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Neurodegenerative Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Neurodegenerative Diseases Drug Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Neurodegenerative Diseases Drug Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Neurodegenerative Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Neurodegenerative Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Neurodegenerative Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Neurodegenerative Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Neurodegenerative Diseases Drug Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Neurodegenerative Diseases Drug Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Neurodegenerative Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Neurodegenerative Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Neurodegenerative Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Neurodegenerative Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Neurodegenerative Diseases Drug Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Neurodegenerative Diseases Drug Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2022-2027) & (US$ Million)
Table 64. Biogen Company Details
Table 65. Biogen Business Overview
Table 66. Biogen Neurodegenerative Diseases Drug Product
Table 67. Biogen Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 68. Biogen Recent Development
Table 69. Pfizer Company Details
Table 70. Pfizer Business Overview
Table 71. Pfizer Neurodegenerative Diseases Drug Product
Table 72. Pfizer Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 73. Pfizer Recent Development
Table 74. Roche Company Details
Table 75. Roche Business Overview
Table 76. Roche Neurodegenerative Diseases Drug Product
Table 77. Roche Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 78. Roche Recent Development
Table 79. Novartis Company Details
Table 80. Novartis Business Overview
Table 81. Novartis Neurodegenerative Diseases Drug Product
Table 82. Novartis Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 83. Novartis Recent Development
Table 84. Sanofi Company Details
Table 85. Sanofi Business Overview
Table 86. Sanofi Neurodegenerative Diseases Drug Product
Table 87. Sanofi Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 88. Sanofi Recent Development
Table 89. Teva Pharmaceuticals Company Details
Table 90. Teva Pharmaceuticals Business Overview
Table 91. Teva Pharmaceuticals Neurodegenerative Diseases Drug Product
Table 92. Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 93. Teva Pharmaceuticals Recent Development
Table 94. Orion Pharma Ltd Company Details
Table 95. Orion Pharma Ltd Business Overview
Table 96. Orion Pharma Ltd Neurodegenerative Diseases Drug Product
Table 97. Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 98. Orion Pharma Ltd Recent Development
Table 99. UCB S.A Company Details
Table 100. UCB S.A Business Overview
Table 101. UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 102. UCB S.A Recent Development
Table 103. ACADIA Pharmaceuticals Inc. Company Details
Table 104. ACADIA Pharmaceuticals Inc. Business Overview
Table 105. ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Product
Table 106. ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 107. ACADIA Pharmaceuticals Inc. Recent Development
Table 108. Lundbeck Pharmaceuticals Italy S.p.A. Company Details
Table 109. Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
Table 110. Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Product
Table 111. Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 112. Lundbeck Pharmaceuticals Italy S.p.A. Recent Development
Table 113. Mitsubishi Tanabe Pharma America Company Details
Table 114. Mitsubishi Tanabe Pharma America Business Overview
Table 115. Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Product
Table 116. Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2016-2021) & (US$ Million)
Table 117. Mitsubishi Tanabe Pharma America Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neurodegenerative Diseases Drug Market Share by Type: 2020 VS 2027
Figure 2. Immunomodulator Features
Figure 3. Interferons Features
Figure 4. Decarboxylase Inhibitors Features
Figure 5. Dopamine Agonists Features
Figure 6. Others Features
Figure 7. Global Neurodegenerative Diseases Drug Market Share by Application: 2020 VS 2027
Figure 8. Multiple Sclerosis Case Studies
Figure 9. Parkinson’s Disease Case Studies
Figure 10. Alzheimer’s Disease Case Studies
Figure 11. Spinal Muscular Atrophy (SMA) Case Studies
Figure 12. Others Case Studies
Figure 13. Neurodegenerative Diseases Drug Report Years Considered
Figure 14. Global Neurodegenerative Diseases Drug Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Neurodegenerative Diseases Drug Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Neurodegenerative Diseases Drug Market Share by Regions: 2020 VS 2027
Figure 17. Global Neurodegenerative Diseases Drug Market Share by Regions (2022-2027)
Figure 18. Global Neurodegenerative Diseases Drug Market Share by Players in 2020
Figure 19. Global Top Neurodegenerative Diseases Drug Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neurodegenerative Diseases Drug as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Neurodegenerative Diseases Drug Revenue in 2020
Figure 21. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2016-2021)
Figure 22. Global Neurodegenerative Diseases Drug Revenue Market Share by Type (2022-2027)
Figure 23. North America Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Neurodegenerative Diseases Drug Market Share by Type (2016-2027)
Figure 25. North America Neurodegenerative Diseases Drug Market Share by Application (2016-2027)
Figure 26. North America Neurodegenerative Diseases Drug Market Share by Country (2016-2027)
Figure 27. United States Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Neurodegenerative Diseases Drug Market Share by Type (2016-2027)
Figure 31. Europe Neurodegenerative Diseases Drug Market Share by Application (2016-2027)
Figure 32. Europe Neurodegenerative Diseases Drug Market Share by Country (2016-2027)
Figure 33. Germany Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Neurodegenerative Diseases Drug Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Neurodegenerative Diseases Drug Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Neurodegenerative Diseases Drug Market Share by Region (2016-2027)
Figure 43. China Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Neurodegenerative Diseases Drug Market Share by Type (2016-2027)
Figure 51. Latin America Neurodegenerative Diseases Drug Market Share by Application (2016-2027)
Figure 52. Latin America Neurodegenerative Diseases Drug Market Share by Country (2016-2027)
Figure 53. Mexico Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Neurodegenerative Diseases Drug Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Neurodegenerative Diseases Drug Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Neurodegenerative Diseases Drug Market Share by Country (2016-2027)
Figure 59. Turkey Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Neurodegenerative Diseases Drug Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Biogen Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 63. Pfizer Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 64. Roche Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 65. Novartis Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 66. Sanofi Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 67. Teva Pharmaceuticals Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 68. Orion Pharma Ltd Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 69. UCB S.A Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 70. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 71. Lundbeck Pharmaceuticals Italy S.p.A. Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 72. Mitsubishi Tanabe Pharma America Revenue Growth Rate in Neurodegenerative Diseases Drug Business (2016-2021)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

以下、関連資料のご紹介

世界の神経変性疾患市場規模・現状・予測（2021年-2027年）

Global Neurodegenerative Disease Market Size, Status and Forecast 2021-2027
QYR2104Z4087 2021年4月 90Pages
QYResearch社発行の本調査資料では、神経変性疾患のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（NMDA、SSRI、ドーパミン阻害剤）、用途別市場規模（パーキンソン病、ハンチントン病、筋萎縮性側索硬化症、アルツハイマー病）、主要地域別市...

世界のドラッグリポジショニング市場規模・現状・予測（2021年-2027年）

Global Drug Repurposing Market Size, Status and Forecast 2021-2027
QYR2104Z1992 2021年4月 96Pages
QYResearch社発行の本調査資料では、ドラッグリポジショニングのグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（腫瘍、中枢神経系疾患、神経変性疾患、その他）、用途別市場規模（病院、外来手術センター、その他）、主要地域別市場規模（北米、アメリ...

世界の孤児肺疾患治療市場規模・現状・予測（2021年-2027年）

Global Orphan Lung Diseases Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z4327 2021年4月 92Pages
QYResearch社発行の本調査資料では、孤児肺疾患治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（免疫抑制剤、抗炎症剤、抗線維化剤、血管拡張剤、コルチコステロイド、CFTRモジュレーター、その他）、用途別市場規模（病院薬局、ドラッグスト...

世界の伝染病治療市場規模・現状・予測（2021年-2027年）

Global Treatment for Communicable Diseases Market Size, Status and Forecast 2021-2027
QYR2104Z5738 2021年4月 96Pages
QYResearch社発行の本調査資料では、伝染病治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（HIV、インフルエンザ、結核、マラリア、肝炎、HPV）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ...

世界の感染性疾患治療市場規模・現状・予測（2021年-2027年）

Global Communicable Diseases Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z1490 2021年4月 93Pages
QYResearch社発行の本調査資料では、感染性疾患治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（HIV、インフルエンザ、結核、マラリア、肝炎、HPV）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨ...

世界の感染性疾患治療市場規模・現状・予測（2021年-2027年）

Global Communicable Diseases Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z1489 2021年4月 95Pages
QYResearch社発行の本調査資料では、感染性疾患治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（HIV、インフルエンザ、結核、マラリア、肝炎、HPV）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨ...

世界の後天性孤児造血疾患治療市場規模・現状・予測（2021年-2027年）

Global Acquired Orphan Blood Diseases Therapeutics Market Size, Status and Forecast 2021-2027
QYR2104Z0031 2021年4月 96Pages
QYResearch社発行の本調査資料では、後天性孤児造血疾患治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（投薬、骨髄移植、輸血、鉄療法）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア...

世界の黄斑変性症（AMD）・その他網膜疾患市場規模・現状・予測（2021年-2027年）

Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size, Status and Forecast 2021-2027
QYR2104Z3524 2021年4月 97Pages
QYResearch社発行の本調査資料では、黄斑変性症（AMD）・その他網膜疾患のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（黄斑変性症、糖尿病性黄斑浮腫、糖尿病性網膜症（DR）、網膜静脈閉塞症、加齢性黄斑変性症（wAMD）、加齢性黄斑変性症...

世界の豚病気治療市場規模・現状・予測（2021年-2027年）

Global Swine Diseases Treatment Market Size, Status and Forecast 2021-2027
QYR2104Z5522 2021年4月 96Pages
QYResearch社発行の本調査資料では、豚病気治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（滲出性皮膚炎、コクシジウム症、呼吸器疾患、豚赤痢、乳腺炎、ブタパルボウイルス）、用途別市場規模（私立獣医病院、私立獣医薬局、政府獣医クリニック...

世界のリソソーム蓄積症市場規模・現状・予測（2021年-2027年）

Global Lysosomal Storage Diseases Market Size, Status and Forecast 2021-2027
QYR2104Z3509 2021年4月 91Pages
QYResearch社発行の本調査資料では、リソソーム蓄積症のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（酵素補充療法、基質減少療法、シスチン枯渇剤）、用途別市場規模（病院、外来手術センター）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、...

世界の神経変性疾患市場規模・現状・予測（2021年-2027年） Neurodegenerative disease or neurodegeneration refers to the progressive damage or wear and tear of the nerve cells. Neurodegenerative disease causes loss of abilities like decision making and eventually memory loss. Market Analysis and Insights: Global Neurodegenerative Disease Market The global Ne…
世界の神経変性疾患市場 2021：企業別、地域別、種類・用途別 The Neurodegenerative Disease market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regul…
世界の脊髄性筋萎縮症治療市場規模・現状・予測（2021年-2027年） Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy ) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. It's not currently possible to cure spinal muscular at…
世界の脊髄性筋萎縮症市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Spinal Muscular Atrophy Market The global Spinal Muscular Atrophy market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data integrity, the re…
世界の脊髄性筋萎縮症（SMA）治療市場規模・現状・予測（2021年-2027年） Spinal muscular atrophy (SMA) refers to a group of inherited diseases that affects the functioning of muscles because of deterioration. North America dominates the global market for SMA treatment due to the high prevalence of SMA and increased adoption of SMA treatment options in the region. Market …